Arcus Biosciences, INC 10-Q quarterly reports

Arcus Biosciences reported a net loss of $128 million for Q1 2026, an increase from the prior year, driven by lower collaboration revenues and continued investment in late-stage development.

Arcus Biosciences reported a significant increase in net loss for Q3 2025 despite advancing its late-stage clinical pipeline and securing new collaboration milestones.

Arcus Biosciences achieved net income in Q2 2025, driven by a one-time revenue adjustment, while advancing key oncology programs and securing a strong cash position.

Arcus Biosciences reports a net loss of $112 million for Q1 2025, while highlighting progress in its casdatifan program and a strategic shift away from a Phase 3 study for etrumadenant in third-line metastatic colorectal cancer.

Arcus Biosciences reports a net loss of $92 million for the third quarter of 2024, with total revenues reaching $48 million, primarily driven by collaboration agreements.

Arcus Biosciences reports a net loss of $97 million for the first half of 2024, while highlighting progress in clinical trials and strategic collaborations.

Arcus Biosciences' first quarter of 2024 saw a significant increase in revenue due to a collaboration amendment with Gilead, alongside ongoing clinical development progress.